#USA #Seattle #Therapeutic Plasma Exchange #GlycanAge #Aging Biomarkers

Glycans: A Revolutionary Insight into Aging

Recent research has put the spotlight on glycans, specifically IgG glycans, as powerful biomarkers for biological aging. A ground-breaking analysis involving over 20,000 individuals across 42 studies established these glycans not only as reliable predictors of all-cause mortality but also highlighted the possibility of reversing aging through therapeutic interventions, particularly therapeutic plasma exchange (TPE).

The study, led by Professor Gordan Lauc of GlycanAge in collaboration with researchers from prestigious institutions, presents unprecedented insights into the role of glycans in aging. The findings reveal that IgG glycome is uniquely modifiable, thereby paving the way for innovative therapeutic strategies aiming at age-related conditions and overall healthspan extension.

The Research: Major Findings

The comprehensive research analyzed data collected from 2008 to 2025 and emphasized how glycan aging correlates significantly with disease and mortality risk. One of the standout findings is that IgG glycome not only serves as a predictor of mortality but is also responsive to various interventions.

Three potential approaches were evaluated: TPE, hormone replacement therapy (HRT), and caloric restriction. Among these, TPE demonstrated the most remarkable results, showing the largest effect on biological age, thereby underlining its potential as a revolutionary treatment in longevity medicine.

Professor Lauc's statement highlights the importance of evidence-based approaches in the longevity domain. 'Many interventions in this space lack rigorous clinical evaluation. TPE, however, is backed by structured studies demonstrating measurable biological effects,' he stated. This framework allows for quantifying impacts on chronic inflammation and immune aging, providing a robust foundation for clinical application.

TPE: A Glimpse into the Future

With over 50 years of clinical applications, TPE has primarily been used to treat conditions like autoimmune diseases. Its recent association with healthspan enhancement has gained traction, thanks to randomized, placebo-controlled trials yielding impressive results. In a notable trial, published in Aging Cell, biweekly TPE sessions along with intravenous immunoglobulin (IVIG) sessions led to an average reduction of 2.6 years in biological age.

Moreover, a recent preprint highlighted even further potential, showcasing that monthly TPE sessions could reduce glycan age by an astonishing 0.4 years per month. This staggering rejuvenation effect underscores the promising future of TPE as a regenerative therapy.

The Path Forward

The implications of this research extend far beyond academic confines, signaling a paradigm shift in how we understand aging. Connections between mechanistic insights and tangible patient outcomes are becoming more evident with each study, further bridging the gap between laboratory findings and real-world applications.

Eric Verdin, co-founder of Circulate Health, emphasized how this research is pushing longevity science into new territories. 'We are moving towards more rigorous approaches that enable us to extend healthspan effectively,' he remarked.

As the scientific community aligns with the Biomarkers of Aging Consortium's criteria for valid aging biomarkers, the fruits of this collaboration highlight the need for structured research and evidence-based protocols in longevity treatments. TPE, with its capacity for modifiable impact on aging, may be at the forefront of this scientific revolution.

In conclusion, as GlycanAge continues its quest to redefine biological age metrics, the findings on glycans offer a beacon of hope in the pursuit of extended health and longevity. With ongoing research and development, the intersection of science and practical health applications stands to transform lives and healthcare standards around the globe.

For more information about this research or inquiries, contact Ana Cvetko, PhD at [Ana's email].

About GlycanAge

GlycanAge is at the forefront of measuring biological age and chronic inflammation. Founded by Professor Gordan Lauc, the acclaimed glycobiologist, it offers innovative solutions utilizing the